Eli Lilly’s Drug Slashes Heart Disease Risk by 95%, Changing Lives

A revolutionary breakthrough in heart disease treatment has been unveiled by Eli Lilly, with its experimental drug, lepodisiran, showing dramatic results in reducing lipoprotein(a) or Lp(a)—a major risk factor for heart attacks, strokes, and other cardiovascular issues. In a Phase 2 trial, a single 400 mg dose of lepodisiran resulted in an average 93.9% reduction in Lp(a) levels after just six months. The drug’s extraordinary potential was further highlighted by the fact that participants continued to show near 95% reductions in Lp(a) for up to 1.5 years, with some individuals experiencing lasting effects. This treatment represents a beacon of hope for millions, especially the 1.4 billion people worldwide suffering from high Lp(a) levels, for whom no approved treatments currently exist. With a groundbreaking ability to deliver long-term effects with infrequent dosing, lepodisiran could revolutionize cardiovascular care. Eli Lilly's ongoing Phase 3 trials hold the promise of confirming whether this drug can also prevent heart attacks and strokes, making it a potential life-saving option for patients at high cardiovascular risk.
https://antcapital.blogspot.com/2025/03/urgent-breakthrough-eli-lillys-drug.html

Urgent Breakthrough: Eli Lilly’s Drug Slashes Heart Disease Risk Factor